Skip to main content
. 2020 Jan 21;2020:9696285. doi: 10.1155/2020/9696285

Figure 2.

Figure 2

Analysis of the relationship between LINC00284 expression and prognosis in patients with serous ovarian carcinoma based on TCGA (a) and TCGA/GEO (b–d) datasets. (a, b) Patients with LINC00284 overexpression had shorter overall and progression-free survival than those with low LINC00284 expression (P < 0.05 and P < 0.001, respectively). (c, d) Patients with serous ovarian carcinoma (SOC) and LINC00284 overexpression treated with chemotherapeutic drugs including taxol/platin combinations had shorter overall and progression-free survival (P < 0.01 and P < 0.0001, respectively).